查詢結果分析
來源資料
頁籤選單縮合
題名 | 臺灣地區各層級醫療院所藥費成長趨勢探析--以2000年至2002年為例=The Growth Trends of NHI Drug Expenditure on Different Levels of Health Care Organizations from 2000 to 2002 |
---|---|
作者 | 陳志麟; 葉德豐; 王俊文; 顏志偉; | 書刊名 | 健康保險雜誌 |
卷期 | 2:2 民95.03 |
頁次 | 頁57-71 |
分類號 | 412.24 |
關鍵詞 | 藥品利用; 藥價調整政策; 藥品費用; 全民健康保險; Drug utilization; Drug reimbursement adjustment policy; Drug expenditure; National health insurance; |
語文 | 中文(Chinese) |
中文摘要 | 臺灣的健保藥費支出所佔之比率一直高居不下,從中央健康保險局健保資料庫的統計數據中,在1999年公告實施之「全民健康保險藥品支付價格調整作業要點」進行藥價調查之後,自2000年開始的藥費成長率都維持在7%以下,尤其是2000年及2001年成長率僅為3.1%及2.2%。因此本研究擬就1999年實施藥價調整政策後至2002年間,藥品利用之趨勢對藥價增長的影響程度,進行政策影響評估之探討。 本研究所採行之分析方法主要為次級資料處理分析,依據AHF藥理分類之主藥理,統計分析2000年1月起至2002年12月止,各層級醫療院所向健保局申報藥品總金額排名前一千品項之各年度藥費及成長率之變化趨勢。 研究結果發現2000年至2002年之間依AGFS藥理分類架構下,我國健保藥品費用佔率最高依序為心臟血管藥物、抗感染劑、中樞神經系統藥物、腸胃道藥物、荷爾蒙劑與合成取代物質,且各層級差異不大。其中抗感染劑、腸胃道藥物及維他命則分別因為政策的管制而導致於2001年呈現負成長,未分類藥物則因多為新藥而大幅成長。 本研究根據研究結果提出下列建議:一、藥理分類定義建議中央主管機關應更明確,特別是末分類治療藥物,以落實藥價管控之目的。二、建議對高價或高使用量藥品作重點管控,以達到藥價管控政策之目的。 |
英文摘要 | The drug expenditure has always been a heavy financial burden to National Health Insurance in Taiwan. In view of the radical increase in drug expenditure and its growth rate, Bureau of National Health Insurance (BNHI) announced a drug reimbursement adjustment policy for drug utilization and expenditure aiming at controlling the drug expenditure to a reasonable level in 1999. Eventually, the expenditure growth rte on drug utilization has been decreasing from around 7% in 2000 to 3.1% in 2001, and then to 2.2% in 2002. Data being analyzed is obtained from the BNHI, starting from January 2000 to December 2002. Only the top 1000 drugs out of about 4000 drugs ranked by their total expenditures within the period of study will be selected, which have already constitute over 70% of the total amount on drug expenditure. The expenditure trend is analyzed by AHFS classification and level of health care organizations. According to AHFS, cardiovascular, anti-infection, central nerve system, gastrointestinal and hormone are the highest rank of drug utilization from 2000 to 2002. There is no significant difference between different level healthcare organizations. There are negative growths in anti-infection, gastrointestinal, and vitamin in 2001 because of the restriction policy. Unclassified drug increase significantly because it conclude most items of new drugs. According to results, the study suggests as following: (1) for controlling the drug price, the definition of drug classification, especially in unclassified drugs, must be identified more clearly, (2) focus the high price or high utilization items. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。